Comparison of Single Intravitreal Injection of Triamcinolone or Bevacizumab for the Treatment of Diabetic Macular Edema

• Status: Completed
• Trial end date: 2008-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare a single intravitreal injection of 4.0 mg of triamcinolone acetonide and 1.25 mg of bevacizumab for the treatment of diabetic macular edema.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Universidade Federal de Goias
• Treatments: Bevacizumab; Triamcinolone; Triamcinolone Acetonide; Triamcinolone diacetate; Triamcinolone hexacetonide

Criteria

Inclusion Criteria:

• Diabetic macular edema with central foveal measurement over 300 micrometers

Exclusion Criteria:

• Glaucoma

• Vitreoretinal surgery

• Cataract Surgery less than 3 months prior inclusion

• Unilateral cataract surgery

• Uncontrolled Glycosylated Hemoglobin

• Previous Intraocular Injection

• Systemic Corticosteroids less than 1 month prior inclusion

• Macular ischemia at Fluorescein Angiography

• Cataract precluding fundus examination

• Active Proliferative Diabetic Retinopathy